ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,745Medicare Part D Prescriptions Filled, Including Refills

Rank: 216 out of 1185

$473K Total Retail Price of All Prescriptions

Rank: 302 out of 1185

375 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
38% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Carolina
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

10% of this provider’s 375 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

0% of this provider’s 7,168 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Carolina
SIMVASTATIN 482 396 1 5
LISINOPRIL 340 195 2 4
LEVOTHYROXINE SODIUM 333 291 3 3
PRAVASTATIN SODIUM 321 245 4 7
OMEPRAZOLE 288 209 5 6
HYDROCODONE-ACETAMINOPHEN 278 163 S3 6 2
ZOLPIDEM TARTRATE 274 167 7 15
AMLODIPINE BESYLATE 270 233 8 1
METOPROLOL TARTRATE 236 186 9 10
NEXIUM 217 168 10 19
HYDROCHLOROTHIAZIDE 196 161 11 12
ATORVASTATIN CALCIUM 176 120 12 11
TRAMADOL HCL 176 114 12 16
FUROSEMIDE 172 140 14 8
GEMFIBROZIL 164 107 15 119
METFORMIN HCL ER 156 114 16 35
MELOXICAM 145 104 17 27
LISINOPRIL-HYDROCHLOROTHIAZIDE 141 110 18 14
GABAPENTIN 141 78 18 13
LOSARTAN POTASSIUM 139 101 20 26
CITALOPRAM HBR 127 80 21 22
PROAIR HFA 121 88 22 50
SERTRALINE HCL 121 90 22 25
PANTOPRAZOLE SODIUM 112 86 24 58
FENOFIBRATE 109 76 25 55
RANITIDINE HCL 108 71 26 17
CRESTOR 97 88 27 23
GLIPIZIDE XL 97 66 27 95
FLUTICASONE PROPIONATE 96 70 29 29
GLIPIZIDE ER 90 47 30 77
LOSARTAN-HYDROCHLOROTHIAZIDE 89 87 31 36
METOPROLOL SUCCINATE 89 49 31 20
METFORMIN HCL 87 54 33 9
LANTUS SOLOSTAR 85 59 34 104
ATENOLOL 78 74 35 28
ALENDRONATE SODIUM 73 73 36 40
VENTOLIN HFA 72 36 37 83
POTASSIUM CHLORIDE 66 47 38 18
ENALAPRIL MALEATE 65 51 39 65
ADVAIR DISKUS 59 51 40 54
AZITHROMYCIN 56 42 41 39
NABUMETONE 56 42 41 165
TRAZODONE HCL 55 33 43 38
DILTIAZEM 24HR ER 53 50 44 143
TERAZOSIN HCL 53 33 44 155
CLOPIDOGREL 50 41 46 31
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 20, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.